QT Imaging Holdings Inc (QTI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.64-4.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · QTI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -68.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 93.0% |
Growth built into the price is above our model estimate.
The price assumes 161.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
QTI — officer change
Dated 2026-08-31
CEO — Dr. Raluca Dinu: The filing discloses a routine equity compensation grant to the sitting CEO, not a change in management or departure.
Why it matters: A successful placement would show the company can follow its international plans. It would also help build clinical evidence.
Supportive ifAnnouncement of the Breast Acoustic CT scanner being placed at Rambam Health Care Campus in Israel.
Worry ifA delay or failure to place the scanner shows there are operational challenges.
Why it matters: The offering can change the capital structure and affect investor trust.
Watch forSuccessful completion of the share offering with strong demand.
Also watch forLow demand for the share offering or strong investor pushback.
Why it matters: If revenue growth speeds up, it may help QT Imaging's performance in a maturing sector.
Supportive ifSector revenue growth shows a rise back toward 10% or higher.
Worry ifSector revenue growth remains below 10% or continues to slow.
Why it matters: Sales growth in the UAE would show that international expansion is working.
Supportive ifSales from the UAE reach or exceed the committed minimum order quantities of 7 scanners in 2026.
Worry ifSales from the UAE do not meet minimum order amounts. This raises concerns about strategy.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$211 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $651 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,535 loss on $10,000 · 65.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More FDA approvals could improve products and help them gain market acceptance.
Supportive ifFDA cleared new product updates or changes.
Worry ifNo new FDA approvals were announced. This may delay product development.
Why it matters: Successful use of the code would help with payments and increase technology use.
Supportive ifThe new CPT code will be used by healthcare providers starting January 2027.
Worry ifIf healthcare providers do not use the CPT code, payment options will be limited.
Why it matters: This offering's success can affect how money is spent and future growth plans.
Watch forThe offering is fully subscribed and raises at least $10 million.
Also watch forThe offering does not attract enough interest, raising less than $5 million.
Why it matters: New approvals would help access the market. They would also support growth plans.
Supportive ifNew approvals for Breast Acoustic CT scanners in Europe were announced.
Worry ifNo new regulatory approvals were announced. This may mean delays in expansion.
Why it matters: This code could improve reimbursement rates. It may also help the technology be used more.
Supportive ifThere were announcements of more use and payment approvals with the new CPT code.
Worry ifNo change in adoption rates or reimbursement issues arise despite the new code.
Why it matters: Good results could prove the technology works. This may help more people use it.
Watch forThe clinical study at Rambam Health Care Campus shows good results.
Also watch forStudy results show poor performance or no important findings.
Why it matters: New agreements can drive sales growth and help reach the $39M revenue target for 2026.
Supportive ifAt least one new distribution deal will be announced in the next quarter.
Worry ifNo new distribution deals are announced in the next quarter. This shows slower growth.
Why it matters: Meeting this target would confirm the company is on track for its $39 million annual goal.
Supportive ifQ3 revenue reported at or above $9.7 million, keeping the annual guidance intact.
Worry ifQ3 revenue was below $9.7 million. This raises worries about meeting the annual target.
Why it matters: Going over this number shows strong demand. It also shows good sales performance.
Supportive ifQ3 scanner shipments reported at over 30 units.
Worry ifQ3 scanner shipments were below 30 units. This suggests weaker demand.